Architecture firm Jestico + Whiles has received planning permission for a new office and conference center at the AstraZeneca site on the Cambridge Biomedical Campus. The building will sit within a broader masterplan originally developed by Herzog & de Meuron, the Swiss practice responsible for shaping the pharmaceutical company's expanding presence in the city. The approval marks another step in what has become one of the most significant corporate campus developments in the United Kingdom's life sciences sector.
AstraZeneca's decision to consolidate its global research and corporate operations in Cambridge has been unfolding for over a decade. The company relocated its headquarters from London to the Cambridge Biomedical Campus, one of Europe's largest clusters of health science activity, where proximity to the University of Cambridge, Addenbrooke's Hospital, and a dense ecosystem of biotech startups creates a concentration of talent and institutional knowledge difficult to replicate elsewhere.
A campus shaped by layers of design authorship
The involvement of Herzog & de Meuron in the site's masterplan established a high architectural benchmark from the outset. The Basel-based firm, known for projects ranging from Tate Modern in London to the Elbphilharmonie in Hamburg, brought a design framework intended to unify the campus as it grows over time. Within that framework, individual buildings can be delivered by different practices — a model common in large-scale campus developments where a single masterplanner sets spatial rules, massing guidelines, and landscape strategies, while other firms design specific structures.
Jestico + Whiles, a London-based practice with a portfolio spanning hospitality, residential, and workplace design, now joins that roster. The firm's commission for an office and conference facility suggests a building oriented toward corporate functions — meetings, internal collaboration, and external engagement — rather than laboratory or research space. Conference centers on pharmaceutical campuses often serve a dual role: they host scientific symposia and investor-facing events, functioning as both operational infrastructure and a form of institutional representation.
The design challenge in such commissions lies in responding to the masterplan's architectural language while asserting enough identity to justify a distinct authorship. Campus buildings that defer too completely to a masterplan risk anonymity; those that diverge too sharply risk incoherence. How Jestico + Whiles navigates that tension will become visible as the project advances toward construction.
Cambridge as a life sciences magnet
The approval also reflects a broader pattern in Cambridge's built environment. The city has experienced sustained demand for laboratory, office, and mixed-use space driven by the life sciences and technology sectors. The Cambridge Biomedical Campus itself has attracted not only AstraZeneca but also the Royal Papworth Hospital and a growing number of research institutes and commercial tenants. Planning approvals for new buildings on the campus have become regular occurrences, each one adding density to a site that functions increasingly like a small district rather than a traditional hospital campus.
This growth has not been without friction. Cambridge faces persistent constraints around housing affordability, transport infrastructure, and the tension between preserving the city's historic character and accommodating the spatial demands of a globally competitive research economy. Every new building approved on the biomedical campus is, in part, a bet that the infrastructure around it — roads, rail, housing, public services — will keep pace.
For AstraZeneca, the calculus is more straightforward. The company has committed to Cambridge as its strategic center of gravity, and each new facility deepens that commitment. For Jestico + Whiles, the project offers a chance to demonstrate competence at the intersection of corporate architecture and science-driven placemaking, within a framework set by one of the world's most recognized practices. Whether the resulting building becomes a notable addition to the campus or simply a competent one will depend on decisions still being made at the drawing board.
With reporting from Architects Journal.
Source · Architects Journal
